Biodexa (NASDAQ:BDRX) stock shot up 70% in morning trading Thursday after the company re-released positive data from a Phase 2 study for its drug eRapa in the treatment of Familial Adenomatous ...

Biodexa (NASDAQ:BDRX) stock soared 76% in morning trading after the company announced it has received FDA Fast Track designation for its drug eRapa for the treatment of familial adenomatous ...

Biodexa believes eRapa could be the first therapeutic option to treat this precancerous condition. 12-month data from a phase 2 clinical trial were recently presented at the 2024 InSIGHT biannual ...

said Stephen Stamp, CEO and CFO of Biodexa Pharmaceuticals PLC.“We are committed to providing global access to eRapa for as many patients as may benefit. This designation is an important step in ...

The designation was requested based on the potential for eRapa to address an unmet medical need for FAP, a condition which left untreated universally leads to colorectal cancer. Today, the only ...

We are delighted to be working with the Emtora team which has excelled in bringing eRapa close to the end of Phase 2 in Non-muscle Invasive Bladder Cancer and to the beginning of a Phase 3 trial ...

The planned registrational Phase 3 study of eRapa in FAP will be a double-blind placebo-controlled trial in 168 patients, randomized 2:1 drug / placebo. It is expected the study will be conducted ...

Encapsulated rapamycin is expected to prevent disease progression by inhibiting mTOR, a protein kinase that has been shown to be overexpressed in FAP polyps. The Food and Drug Administration (FDA ...

The U.S. component of the study will be conducted by LumaBridge, based in San Antonio, Texas. The planned registrational Phase 3 study of eRapa in FAP will be a double-blind placebo-controlled trial ...

The designation was requested based on the potential for eRapa to address an unmet medical need for FAP, a condition which left untreated universally leads to colorectal cancer. Today, the only ...